Detalhe da pesquisa
1.
Capivasertib in Hormone Receptor-Positive Advanced Breast Cancer.
N Engl J Med
; 388(22): 2058-2070, 2023 Jun 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37256976
2.
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.
N Engl J Med
; 387(1): 9-20, 2022 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35665782
3.
TROPION-Breast01: Datopotamab deruxtecan vs chemotherapy in pre-treated inoperable or metastatic HR+/HER2- breast cancer.
Future Oncol
; 20(8): 423-436, 2024 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-37387213
4.
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates.
Breast Cancer Res
; 25(1): 4, 2023 01 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36635767
5.
Abemaciclib plus fulvestrant in East Asian women with HR+, HER2- advanced breast cancer: Overall survival from MONARCH 2.
Cancer Sci
; 114(1): 221-226, 2023 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-36168844
6.
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer.
N Engl J Med
; 382(7): 610-621, 2020 02 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-31825192
7.
Impact of Anti-HER2 Therapy Alone and With Weekly Paclitaxel on the Ovarian Reserve of Young Women With HER2-Positive Breast Cancer.
J Natl Compr Canc Netw
; 21(1): 33-41.e16, 2023 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36634607
8.
Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer.
N Engl J Med
; 381(4): 307-316, 2019 07 25.
Artigo
em Inglês
| MEDLINE | ID: mdl-31166679
9.
Blood Test for Breast Cancer Screening through the Detection of Tumor-Associated Circulating Transcripts.
Int J Mol Sci
; 23(16)2022 Aug 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-36012405
10.
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial.
Lancet Oncol
; 22(9): 1275-1289, 2021 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-34363762
11.
Final results of the randomized phase 2 LEO trial and bone protective effects of everolimus for premenopausal hormone receptor-positive, HER2-negative metastatic breast cancer.
Int J Cancer
; 2021 Apr 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-33905134
12.
Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials.
Cancer Sci
; 112(6): 2381-2392, 2021 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-33686753
13.
Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.
Br J Cancer
; 125(5): 679-686, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34158598
14.
Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial.
Lancet
; 396(10257): 1090-1100, 2020 10 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32966830
15.
Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial.
Lancet Oncol
; 21(1): 60-72, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31806543
16.
Health-Related Quality of Life in MONARCH 2: Abemaciclib plus Fulvestrant in Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer After Endocrine Therapy.
Oncologist
; 25(2): e243-e251, 2020 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-32043763
17.
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib.
Breast Cancer Res Treat
; 184(3): 743-753, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32860168
18.
Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Breast Cancer Res Treat
; 183(1): 107-116, 2020 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-32577940
19.
Correction to: Palbociclib use with grade 3 neutropenia in hormone receptor-positive metastatic breast cancer.
Breast Cancer Res Treat
; 183(2): 493, 2020 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-32661666
20.
Intermediate HER2 expression is associated with poor prognosis in estrogen receptor-positive breast cancer patients aged 55 years and older.
Breast Cancer Res Treat
; 179(3): 687-697, 2020 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-31811505